Collagen News and Research

Latest Collagen News and Research

Suneva Medical commends Trilogy Education for conducting a two-day dermal filler training course for nurses

With the growing use of dermal fillers, ensuring patient safety and satisfaction has never been more important. Dermatology and plastic surgery nurse practitioners continue to play a vital role in managing, educating and interacting with patients. A 2009 study of dermatology nurse practitioners estimates that the average number of patients nurse practitioners see each year totals six hundred million.

13 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

FDA regulatory clearance for Kensey Nash's ECM product

Kensey Nash Corporation, a leading medical technology company that provides innovative resorbable biomaterial technology for a wide range of medical procedures, today announced that it has received 510(k) clearance for its first extracellular matrix (ECM) product, Medeor(TM) Matrix, from the U.S. Food and Drug Administration.

12 Nov 2009

TivaMed changes its name to Viveve

Women's sexual health company, TivaMed, today announced it has changed its name to Viveve as it prepares for a 2010 launch of its Viveve system to OB/GYNs in select U.S. markets.

9 Nov 2009

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009.

6 Nov 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009.

5 Nov 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies demonstrating that human Serum Amyloid P (hSAP) potently inhibited fibrosis in two independent model systems of kidney fibrosis.

5 Nov 2009

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free survival, according to data presented on Tuesday, November 3, 2009 at the 51st American Society for Therapeutic Radiology and Oncology (ASTRO) annual meeting in Chicago, Illinois.

4 Nov 2009

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Cardium Therapeutics today announced plans to submit a 510(k) premarket notification with the U.S. Food and Drug Administration (FDA) seeking marketing clearance of its ExcellagenXL(TM) product candidate.

3 Nov 2009

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

Helix BioMedix, Inc., a developer of bioactive peptides, today announced the completion of a series of three clinical studies investigating the safety and efficacy of a serum, eye cream and moisturizer, each containing the Company’s SmartPeptides™ technology, including the newly developed Heptapeptide-7. These studies demonstrate improvement in skin texture and appearance as well as the decrease in fine lines and wrinkles with Striking™ Skin Care formulations.

28 Oct 2009

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and KOKEN Co., Ltd., a leading atelocollagen company, announced today that Alnylam has granted KOKEN a non-exclusive worldwide license to manufacture and provide RNAi research products and services under the Kreutzer-Limmer patent family.

27 Oct 2009

Wound Management Technologies signs distribution agreement with Biocure S.r.l. of Milan

Wound Management Technologies, Inc., through its subsidiary, Wound Care Innovations, announced today that it has reached an agreement with Biocure S.r.l. of Milan, Italy for the distribution of WNDM's patented molecular form of activated collagen, CellerateRx®.

26 Oct 2009

STAAR Surgical Company reports promising assessments from CAST

STAAR Surgical Company (Nasdaq: STAA), a leading developer, manufacturer and marketer of minimally invasive ophthalmic products today reported that the Collamer Accommodating Study Team (CAST) formed by the company in late 2008 has provided very promising initial patient vision assessments from the first phase of the project.

26 Oct 2009

VASER-Assisted Lipoplasty delivers superior results in skin retraction and blood loss

At the 78th Annual American Society of Plastic Surgeons Annual (ASPS) Meeting, Dr. Paul Vanek presented a study that confirms that VASER-Assisted Lipoplasty (VAL) delivers superior results over traditional Suction-Assisted Lipoplasty (SAL) in skin retraction and blood loss.

26 Oct 2009

Orthovita to present comparative study data of its Cortoss product to polymethylmethacrylate

Orthovita, Inc., an orthobiologics and biosurgery company, is pleased to announce that Dr. Pierce D. Nunley, Director of the Spine Institute of Louisiana, will present his abstract, “A Comparison of Clinical Outcomes and Adjacent Level Fractures in Patients Receiving Vertebroplasty for Osteoporotic Compression Fractures Using CortossTM or PMMA: A Prospective, Randomized Trial,” at the 2009 Annual Meeting of the Congress of Neurological Surgeons (CNS).

24 Oct 2009

First-quarter fiscal 2010 results announced by Kensey Nash

Kensey Nash Corporation, a leading medical technology company that provides innovative solutions and technologies for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2009.

22 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Non-invasive tool to increase facial volume and reverse some of the visible signs of aging

Faces don't lie when it comes to showing signs of aging. Yet gravity alone is not the sole determinant of the aging face. Studies have demonstrated that volume loss of soft tissue and bone is at least equally important to facial aging. The loss of volume in the face over time can cause deep lines, sunken areas around the eyes, temples, nose and jowls.

20 Oct 2009

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

Cardium Therapeutics today announced the publication of positive findings from the open label multi-center Phase 1/2 clinical study of Excellarate(TM) (GAM501, Ad5PDGF-B / 2.6% collagen), its product candidate for the potential treatment of non-healing diabetic foot ulcers.

19 Oct 2009

National Science Foundation funded 2009 Nobel laureates felicitated

The National Science Foundation (NSF) congratulates the 2009 Nobel laureates, particularly those who have received NSF funding over the years: Jack W. Szostak, who shared the prize in physiology or medicine; Thomas A. Steitz, who shared the prize in chemistry; and Elinor Ostrom and Oliver E. Williamson who earned the Sveriges Riksbank Prize in economic sciences in memory of Alfred Nobel 2009.

15 Oct 2009

Collagen News and Research

Latest Collagen News and Research

Suneva Medical commends Trilogy Education for conducting a two-day dermal filler training course for nurses

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

FDA regulatory clearance for Kensey Nash's ECM product

TivaMed changes its name to Viveve

BioSpecifics Technologies revenues increases by 100% for the third quarter ended September 30, 2009

Idera Pharmaceuticals announces financial results for the third quarter of 2009

Study demonstrates potential of human Serum Amyloid P to block very aggressive fibrotic pathology

EUSA Pharma's PROSTASCINT effective in guiding targeted prostate cancer treatment

Cardium Therapeutics to seek FDA marketing clearance for ExcellagenXL

Helix BioMedix' SmartPeptides technology products demonstrate improvement in skin texture

KOKEN receives license to manufacture and provide RNAi research products under Kreutzer-Limmer patent family

Wound Management Technologies signs distribution agreement with Biocure S.r.l. of Milan

STAAR Surgical Company reports promising assessments from CAST

VASER-Assisted Lipoplasty delivers superior results in skin retraction and blood loss

Orthovita to present comparative study data of its Cortoss product to polymethylmethacrylate

First-quarter fiscal 2010 results announced by Kensey Nash

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

Non-invasive tool to increase facial volume and reverse some of the visible signs of aging

Cardium Therapeutics reports positive findings from Excellarate Phase 1/2 clinical study

National Science Foundation funded 2009 Nobel laureates felicitated

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Collagen News and Research

Latest Collagen News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in